Home > News > Nanoforum commercialisation workshop identifies need for greater industrial engagement
June 28th, 2007
Nanoforum commercialisation workshop identifies need for greater industrial engagement
Abstract:
Nanoforum, the thematic network funded by the EU under the Fifth Framework Programme (FP5), has identified three key challenges for the development of nanotechnology in Europe: a low level of venture capital investment, low patenting rates, and low investment from industry
According to the Nanoforum report, the first priority is to increase the very low proportion (only 3.5%) of global nanotechnology venture capital invested in Europe.
Despite public funding being on a par with that of the US, Europe, it seems, is also lagging behind in the number of nanotechnology patents granted. Industrial investment in nanotechnology is also only half that in the US and Japan.
For the authors of the report, the low level of venture capital is largely due to a shortage of suitable investment targets. Companies lack focused business models, commercial experience, and exit strategies. Whilst public funding sources may take the place of venture capital, the concern is that companies will then miss out on the other benefits that investors would bring, such as in-depth industry awareness and networks.
Source:
cordis.europa.eu
Related News Press |
Announcements
What heat can tell us about battery chemistry: using the Peltier effect to study lithium-ion cells March 8th, 2024
Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024
Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers/Posters
Researchers develop artificial building blocks of life March 8th, 2024
Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024
Patents/IP/Tech Transfer/Licensing
Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023
Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||